de Germay, Sibylle http://orcid.org/0000-0001-6545-196X
Conte, Cécile
Rascol, Olivier
Montastruc, Jean-Louis
Lapeyre-Mestre, Maryse
Article History
First Online: 4 June 2020
Compliance with Ethical Standards
:
: The work was performed during the university research time of the authors, without funding agencies.
: All authors declare no support from any organization for the submitted work. Sibylle de Germay, Cécile Conte, Jean-Louis Montastruc, and Maryse Lapeyre-Mestre have no conflict of interest. Independently of this work, Olivier Rascol reports scientific grants from <i>Agence Nationale de la Recherche</i>, <i>Centre Hospitalier Universitaire de Toulouse</i>, France-Parkinson, INSERM-DHOS <i>Recherche Clinique Translationnelle</i>, Michael J Fox Foundation, <i>Programme Hospitalier de Recherche Clinique</i>, European Commission (FP7, H2020), and Cure Parkinson IK; Olivier Rascol has acted as scientific advisor for AbbVie, Adamas, Acorda, Addex, AlzProtect, Apopharma, Astrazeneca, Axovant, Bial, Biogen, Britannia, Buckwang, Cerespir, Clevexel, Denali, INC Research, Lundbeck, Lupin, Merck, MundiPharma, Neuratris, Neuroderm, Novartis, ONO Pharma, Osmotica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Roche, Sanofi, Servier, Sunovion, Théranexus, Takeda, Teva, UCB, Vectura, Watermark Research, XenoPort, XO, and Zambon.